Swiss Nordic Bio carries the tradition of 10 years of Swiss Scandinavian Bio-Business Seminar (SSBBS).
The event will host high ratio of investors and pharma to biotech companies. More than 20 investors and more than 10 scouting/business development executives from pharma/diagnostics companies are expected. This will be an exclusive event with maximum 200 participant in total. It will include investor and partnering panel discussions. There are good opportunities for R&D collaboration between SME, large corporations and academia within EUREKA-Eurostars.
There will be a possibility to pitch your product & business model to leading investors & pharma companies. One-to-one meetings can be booked online. The online company profile will be visible to all participants.
2017 participants so far include: Johnson and Johnson Innovation, Novartis Venture Fund, Occident Group, Redalpine Venture Partners, Capital Rewards Partners, Creathor Venture, Management GmbH, Endeavour Vision SA, Merck Ventures BV, Novo A/S (Ventures), Debiopharm International SA, Lipum AB, F.Hoffmann-La Roche Ltd, Bay City Capital, HBM Partners Ltd., Industrifonden, MTIP MedTech Innovation Partners AG, PM Equity Partner, Signature Seven Partners, Wille Finance AG, XOventure GmbH, Sunstone Capital, Dottikon Exclusive Synthesis AG
